Prime Medicine (PRME) IPO Opens 12% Higher

Today's IPO for Prime Medicine, Inc. (Nasdaq: PRME) opened for trading at $18.97 after pricing its upsized 10,294,118 share offering at $17 per share, the middle of the expected range. The IPO size was raised from 8,900,000 shares.

The IPO open puts the valuation at approximately $1.8 billion.

J.P. Morgan, Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.

Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases.

You May Also Be Interested In